Preparing for stricter standards on substances of human origin
European Pharmaceutical Review
JULY 20, 2023
This may lead to longer development timelines and higher costs for life science companies. States will also retain full competences on ethical decisions regarding the provision of SoHO-based treatments in their respective healthcare systems. Cited 2023Mar].
Let's personalize your content